Form 8-K - Current report:
SEC Accession No. 0001193125-25-161516
Filing Date
2025-07-21
Accepted
2025-07-21 07:30:13
Documents
12
Period of Report
2025-07-21
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d882671d8k.htm   iXBRL 8-K 27078
  Complete submission text file 0001193125-25-161516.txt   138273

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA srpt-20250721.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20250721_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20250721_pre.xml EX-101.PRE 10813
14 EXTRACTED XBRL INSTANCE DOCUMENT d882671d8k_htm.xml XML 3503
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 251135713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)